Healthcare is shifting on multiple fronts simultaneously, from how doctors get paid to where patients receive care to how treatments are tailored to individual biology. Some of these changes are already visible in everyday medical visits, while others are still working their way into standard practice. Here’s what’s actually happening and what it means for you.
Paying for Results, Not Procedures
The traditional model of healthcare payment is straightforward: a doctor performs a service, and the insurer pays for it. More services mean more revenue, regardless of whether the patient actually gets better. That model is gradually being replaced by value-based care, where hospitals and physicians are financially rewarded (or penalized) based on patient outcomes.
The shift is most visible in how Medicare now handles hospital readmissions. Hospitals track 30-day readmission rates for certain conditions and procedures, and facilities with higher-than-average readmissions lose a percentage of their payment for every discharge. A $10,000 hospital bill, for instance, could trigger a $200 penalty per qualifying program if that hospital’s readmission numbers are too high. Of the major federal quality programs, the Hospital Readmissions Reduction Program has been the most effective at actually bringing readmission rates down.
The broader idea is to shift spending away from expensive acute hospitalizations and toward preventive, long-term management of chronic diseases. That reorientation has the potential to save significant costs over time, though the results so far are mixed. Some hospitals have reduced readmissions and mortality, but the rate of complications that happen during hospital stays hasn’t meaningfully dropped across the board.
Telehealth Found Its Level
Before the pandemic, telehealth barely registered. In January 2020, less than 1% of claims to private insurers involved a virtual visit. Usage spiked during lockdowns and then settled into a new normal: about 4.5% of all U.S. healthcare visits were conducted via telehealth by 2021, and that number held steady through 2022 before ticking up slightly to 4.8% in 2023.
That may sound modest, but it represents a permanent expansion in how care gets delivered. Mental health visits, follow-up appointments, and medication management have proven especially well-suited to video or phone consultations. For patients in rural areas or those with mobility challenges, the option to skip a trip to the clinic isn’t going away.
Hospital Care Is Moving Home
One of the more surprising shifts is the growth of hospital-at-home programs, where patients who would normally be admitted receive acute-level care in their own beds. Clinicians visit, remote monitoring tracks vital signs, and medications and tests are delivered on-site.
A randomized clinical trial of rural patients compared hospital-at-home care with traditional admission. Patients treated at home reported significantly better experiences. Their patient experience scores averaged 13.4 out of a possible range compared to 11.0 for those in the hospital. The net promoter score, a measure of whether patients would recommend the experience, was nearly double: 88 versus 45. Physical activity levels also improved at home, which matters for recovery. Earlier research in urban settings found that home-based acute care was associated with lower mortality, lower costs, fewer readmissions, and fewer discharges to nursing facilities.
Genetic Testing Is Preventing Drug Reactions
One of the most concrete advances in personalized medicine involves testing a patient’s genes before prescribing medication. People metabolize drugs differently based on their genetic makeup, and a medication that works well for one person can cause serious side effects in another. Pharmacogenomic testing identifies those differences upfront.
The largest trial to date, called PREPARE, found that using a panel of genetic tests to guide prescribing reduced adverse drug reactions by 30%. For psychiatric patients specifically, the results were even more striking: those with relevant genetic variants who received gene-guided prescribing saw a 34% reduction in adverse reactions, a 41% reduction in hospitalizations, a 41% drop in readmission rates, and shorter hospital stays overall. This kind of testing is still far from routine, but the evidence supporting it is strong enough that adoption is accelerating.
Gene Therapies Are Reaching Patients
Gene therapy has moved from laboratory concept to approved treatment. In December 2023, the FDA approved the first therapy using CRISPR genome-editing technology, a tool that allows scientists to precisely alter DNA. The treatment, called Casgevy, is approved for sickle cell disease in patients 12 and older who experience recurring pain crises. A second gene therapy for sickle cell, Lyfgenia, was approved the same day using a different approach.
These approvals are significant because sickle cell disease affects roughly 100,000 people in the United States and has historically had limited treatment options. The therapies work by modifying a patient’s own cells and reintroducing them, essentially correcting the genetic root of the disease rather than managing symptoms. They represent the first wave of what’s expected to be a growing category of one-time genetic treatments for conditions that were previously lifelong.
Prescription Apps for Mental Health
A new category of treatment has emerged: prescription software. These are FDA-authorized apps that deliver structured therapy, typically cognitive behavioral therapy, through a smartphone. They’re not wellness apps or meditation tools. They go through regulatory review and require a prescription.
Several are now authorized for mental health conditions. Daylight targets generalized anxiety disorder and showed significant improvements in self-reported symptoms compared to standard online education. MamaLift Plus addresses postpartum depression and outperformed a control app that looked similar but lacked the therapeutic content. Other authorized apps cover insomnia, substance use disorders, and depression. These digital therapeutics don’t replace traditional therapy, but they expand access for patients who face long wait times, live in underserved areas, or need structured support between appointments.
Wearables Are Outpacing the Evidence
Continuous glucose monitors, devices that track blood sugar in real time through a small sensor on the skin, were developed for people with diabetes. Now manufacturers are marketing them to the general population as wellness tools for optimizing energy, diet, and fitness. The consumer appeal is obvious: real-time biofeedback feels empowering.
The problem is that clinicians don’t yet have a clear picture of what normal glucose monitor readings look like in people without diabetes. There have been no large studies establishing reference ranges for this population, which means neither you nor your doctor can easily interpret the data these devices produce. Research is underway to define those ranges, but for now, healthy people using glucose monitors are essentially flying without a map. This pattern, consumer technology racing ahead of clinical evidence, is becoming a recurring theme as wearable health devices proliferate.
A Workforce Under Strain
All of these changes are unfolding against a backdrop of growing workforce shortages. The United States is projected to be short nearly 64,000 nurses by 2030 and roughly 86,000 physicians by 2036. The growth of advanced practice providers like nurse practitioners and physician assistants is expected to absorb some of that gap, but not nearly enough to close it.
This shortage is already reshaping care delivery in ways patients can feel: longer wait times, shorter appointments, and a greater reliance on technology to extend what each clinician can do. Many of the changes described above, from telehealth to hospital-at-home to digital therapeutics, are partly driven by the simple reality that there aren’t enough healthcare workers to meet demand through traditional models. The system isn’t just choosing to evolve. In many cases, it has to.